1887

Journal of Medical Microbiology logo

Volume 60, Issue 8

Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Free

Abstract

The kinetics of bacterial killing for fidaxomicin and its major metabolite, OP-1118, were investigated against strains, including two clinical strains belonging to the restriction endonuclease analysis group BI (ORG 1687 and 1698), the ATCC 43255 strain and two laboratory-derived mutant strains with decreased susceptibility to fidaxomicin (ORG 919 and 1620). Both fidaxomicin and OP-1118 demonstrated time-dependent killing of strains. Fidaxomicin (at 4× MIC) reduced bacterial counts of the ATCC 43255 strain, clinical strain ORG 1687 and the two laboratory-generated mutant strains by ≥3 logs within 48 h of exposure. The other BI strain, ORG 1698, was tested at 2× MIC fidaxomicin with bacterial counts decreasing 1 log in 48 h. Exposure to OP-1118 (at 4× MIC) also resulted in a ≥3 log drop in c.f.u. counts for the ATCC 43255 strain, the clinical BI strain ORG 1687 and the mutant strain ORG 919. Higher concentrations of OP-1118 (32× MIC) were required for a 3 log reduction in c.f.u. counts for the other BI strain, ORG 1698. In summary, the results indicate that both fidaxomicin and its major metabolite, OP-1118, are bactericidal against strains, including the hypervirulent restriction endonuclease analysis group BI strains, at concentrations that are many fold below the detected faecal concentrations of these compounds after oral administration of fidaxomicin.

  • Received:
  • Accepted:
  • Published Online:
© 2011 SGM
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.029470-0
2011-08-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/8/1213.html?itemId=/content/journal/jmm/10.1099/jmm.0.029470-0&mimeType=html&fmt=ahah

References

  1. Ackermann G., Löffler B., Adler D., Rodloff A. C. 2004; In vitro activity of OPT-80 against Clostridium difficile . Antimicrob Agents Chemother 48:2280–2282 [View Article][PubMed]
     [Google Scholar]
  2. Babakhani F. K., Shangle S., Robert N., Sears P., Shue Y. K. 2004; Resistance development, cross-resistance, and synergy studies of OPT-80. In Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA abstract E-2047 Washington, DC: American Society for Microbiology;
     [Google Scholar]
  3. Babakhani F., Seddon J., Robert N., Gomez A., Sears P. 2007; Narrow spectrum activity and low fecal binding of OPT-80 and its major hydrolysis metabolite (OP-1118). In Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA abstract E-2076 Washington, DC: American Society for Microbiology;
     [Google Scholar]
  4. CLSI 2007 Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, 7th edn. Approved Standard M11–A7 Wayne, PA: Clinical and Laboratory Standards Institute;
     [Google Scholar]
  5. Credito K. L., Appelbaum P. C. 2004; Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 48:4430–4434 [View Article][PubMed]
     [Google Scholar]
  6. Crook D., Peto T., Miller M., Louie T., Cornely O., Shue Y. K., Gorbach S. 2010; Efficacy and safety of fidaxomicin (FDX) vs vancomycin (VAN) in Clostridium difficile infection (CDI) in 2 randomized controlled trials (RCT) with 1105 patients. In Abstracts of the 48th Infectious Disease Society of America Annual Meeting, Vancouver, Canada abstract 1417 Arlington, VA: Infectious Disease Society of America;
     [Google Scholar]
  7. Dubberke E. R., Wertheimer A. I. 2009; Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 30:57–66 [View Article][PubMed]
     [Google Scholar]
  8. Finegold S. M., Molitoris D., Vaisanen M. L., Song Y., Liu C., Bolaños M. 2004; In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 48:4898–4902 [View Article][PubMed]
     [Google Scholar]
  9. Johnson S., Homann S. R., Bettin K. M., Quick J. N., Clabots C. R., Peterson L. R., Gerding D. N. 1992; Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 117:297–302 [CrossRef]
     [Google Scholar]
  10. Kurabachew M., Lu S. H., Krastel P., Schmitt E. K., Suresh B. L., Goh A., Knox J. E., Ma N. L., Jiricek J. et al. 2008; Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis . J Antimicrob Chemother 62:713–719 [View Article][PubMed]
     [Google Scholar]
  11. Louie T. J., Emery J., Krulicki W., Byrne B., Mah M. 2009a; OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 53:261–263 [View Article][PubMed]
     [Google Scholar]
  12. Louie T. J., Mullane K. M., Weiss K., Lentnek A., Golan Y., Gorbach S., Sears P., Shue Y. K., Miller M. A. 2009b; A randomised, double-blind clinical trial of OPT-80 versus vancomycin in Clostridium difficile infection. In Abstracts of the 19th European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland abstract 0148 Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases;
     [Google Scholar]
  13. Mekler V., Sineva E., Mukhopadhyay J., Sajida I., Wang X., Kortkhonja E., Donadio S., Ebright R. 2004; Target and mechanism of the transcription inhibitor lipiarmycin. Presented at the Biophysical Society 48th Annual Meeting, Baltimore, MD, USA
     [Google Scholar]
  14. Miller M. 2010; Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. Expert Opin Pharmacother 11:1569–1578 [View Article][PubMed]
     [Google Scholar]
  15. Miller M. A., Mullane K. M., Weiss K., Lentnek A., Golan Y., Gorbach S., Sears P., Shue Y. K., Louie T. J. 2009; OPT-80 versus vancomycin in Clostridium difficile infection: results of a randomized clinical trial. Gastroenterology 136(Suppl. 1)A-115 [CrossRef]
     [Google Scholar]
  16. Miller B. A., Chen L. F., Sexton D. J., Anderson D. J. 2010; The impact of hospital-onset healthcare facility associated Clostridium difficile infection (CDI) in community hospitals: surpassing methicillin-resistant Staphylococcus aureus (MRSA) as the new superbug. In Program and Abstracts of the 5th Decennial International Conference on Healthcare-Associated Infections (ICHAI), Atlanta, Georgia abstract 386
    [Google Scholar]
  17. Odenholt I., Walder M., Wullt M. 2007; Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile . Chemotherapy 53:267–274 [View Article][PubMed]
     [Google Scholar]
  18. Rupnik M., Wilcox M. H., Gerding D. N. 2009; Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7:526–536 [View Article][PubMed]
     [Google Scholar]
  19. Shue Y. K., Sears P. S., Shangle S., Walsh R. B., Lee C., Gorbach S. L., Okumu F., Preston R. A. 2008; Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 52:1391–1395 [View Article][PubMed]
     [Google Scholar]
  20. Sonenshein A. L., Alexander H. B. 1979; Initiation of transcription in vitro inhibited by lipiarmycin. J Mol Biol 127:55–72 [View Article][PubMed]
     [Google Scholar]
  21. Talpaert M., Campagnari F., Clerici L. 1975; Lipiarmycin: an antibiotic inhibiting nucleic acid polymerases. Biochem Biophys Res Commun 63:328–334 [View Article][PubMed]
     [Google Scholar]
  22. Tannock G. W., Munro K., Taylor C., Lawley B., Young W., Byrne B., Emery J., Louie T. 2010; A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 156:3354–3359 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.029470-0
Loading
Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile
J. Med. Microbiol. 60, 1213 (2011); https://doi.org/10.1099/jmm.0.029470-0
/content/journal/jmm/10.1099/jmm.0.029470-0
/content/journal/jmm/10.1099/jmm.0.029470-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error